TAFINLAR (dabrafenib) capsules, for oral use Initial U.S. Approval: 2013

TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. TAFINLAR is indicated, in combination with trametinib, for: • the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. • the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. • the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. • the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options. • the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Medicine Name: TAFINLAR
Generic Name: dabrafenib
Approval Date: 2013
Treatment of: Melanoma…
Company Name: Novartis Pharmaceuticals Corporation.
Source Details: Patient Information

Access Patient Name Basis Treatment

IPN, New Delhi can facilitate patient to import of “TAFINLAR (dabrafenib) capsules” in quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).

Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India. With over two decades of industry experience, IPN offers extensive coverage across India, including prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.

Description

TAFINLAR (dabrafenib) capsules is used to treat BRAF V600E Mutation-Positive Unresectable or Metastatic Melanoma, BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma, Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma, BRAF V600E Mutation-Positive Metastatic NSCLC, BRAF V600E Mutation-Positive Metastatic NSCLC, BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors.

What dabrafenib is and used for?

Dabrafenib, sold under the brand name Tafinlar & Rafinlar ( both by Novartis) among others, is a medication for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF (V600)-mutated metastatic melanoma. The US Food and Drug Administration initially approved dabrafenib as a single agent treatment for patients with BRAF V600E mutation-positive advanced melanoma on May 29, 2013. Dabrafenib was approved for use in the European Union in August 2013. In April 2017, the European Union approved the combination of dabrafenib with trametinib for BRAF V600-positive advanced or metastatic non small-cell lung cancer (NSCLC).

How can 1 go about obtaining TAFINLAR Capsules?

If TAFINLAR (dabrafenib) capsules are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

Note:
We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.

NEWS / UPDATES

For TAFINLAR (dabrafenib) capsulesIndications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors For More Details
Dabrafenib in Combination With Trametinib for Unresectable or Metastatic Solid Tumors With BRAF V600E Mutation For More Details
Pancreatic Cancer Awareness Month: Novel Targeted Therapy in PDAC For More Details

How to buy?

How to buy prescriptions drugs?

Contact Details

Indian Pharma Network
New Delhi:110016 India.

MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
EMAIL ID:
[email protected]

Steps to get access

If you possess a prescription issued by a Registered Medical Practitioner (RMP), IPN in Delhi can aid you in acquiring authentic medication globally. Our experts will furnish you with a detailed, step-by-step guidance on the lawful and secure process of importing prescription medicines based on the particulars you provide.

Step 1. Send a request for your medicine online:-
Applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).

Step 2. Verification of documents:-
We verify your a prescription and necessary documents to import drugs in small quantities for personal use.

Step 3. Permission to Import:-
After getting approval of Drugs Controller General (India), we start the process to import of drugs as mentioned in prescription for personal use.

Step 4. We source your medicine:-
Our expert sourcing team work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.

Step 5. Delivery of medicine:-
After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine.

Documentation Required

Doctor’s Prescription –
We would require prescription from Registered Medical Practitioner (RMP) stating product name, dosage, duration of treatment and diagnosis.

Patient’s Medical history –
We would require all test reports and medical reports of the patient for last 3 months.

Patient’s Identity card –
We will require scan copy of patient’s identity card and proof of residence to initiate documentation process.

About IPN, Delhi

Indian Pharma Network (IPN), Delhi India is a leading Pharmaceutical Distributor / Supplier / Exporter / Importer of Anti-Cancer Medicines can be imported for personal use under “patient name basis”. Indian Pharma Network (IPN) is registered organisation in India, having highly qualified professionals of pharmaceutical Industry. Registration Number : 07AAFFI2544E1ZO under GST Act. Specialized in Oncology Pharmacy. Helped more than 13500 patients. Helps you access to a FDA approved medicines, no matter where you live. Sourcing each medicine for named patient use and overseeing every aspect of the shipping, customs and delivery.

TAFINLAR (dabrafenib) capsules